SCHEMBL5215948

SCHEMBL5215948

Cc1ccc(-n2cc(-c3cnc4ccccc4n3)cn2)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.45
GRM4 Q14833 1/20 0.43
DYRK1B Q9Y463 5/20 0.41
KDR P35968 2/20 0.40
FGFR3 P22607 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
BCHE P06276 2/20 0.39
MAPT P10636 4/20 0.39
PDGFRB P09619 1/20 0.38
FLT3 P36888 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219172 0.88 NPC1 (0.50) NPC1KDRFGFR3MEN1KMT2A
SCHEMBL5215816 0.86 DYRK1B (0.41) NPC1GRM4DYRK1BMEN1KMT2A
SCHEMBL5217439 0.85 NPC1 (0.53) NPC1KDRFGFR3MEN1KMT2A
SCHEMBL5215342 0.85 GRM4 (0.57) NPC1GRM4DYRK1BKDRFGFR3
SCHEMBL5219303 0.84 GRM4 (0.44) NPC1GRM4DYRK1BMEN1KMT2A
SCHEMBL30796007 0.81 GRM5 (0.47) GRM4DYRK1BKDRFLT3
SCHEMBL3923521 0.81 GRM5 (0.47) GRM4DYRK1BKDRFLT3
SCHEMBL5217878 0.81 MAPT (0.45) NPC1DYRK1BKDRFGFR3MEN1
SCHEMBL5219466 0.80 NPC1 (0.48) NPC1GRM4KDRFGFR3MEN1
SCHEMBL5217660 0.80 NPC1 (0.51) NPC1GRM4DYRK1BKDRFGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C NPC1 4205/4885GRM4 8/4885DYRK1B 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.